UK markets close in 32 minutes
  • FTSE 100

    7,803.43
    +42.32 (+0.55%)
     
  • FTSE 250

    20,550.70
    +652.16 (+3.28%)
     
  • AIM

    887.63
    +14.41 (+1.65%)
     
  • GBP/EUR

    1.1239
    -0.0018 (-0.16%)
     
  • GBP/USD

    1.2291
    -0.0081 (-0.65%)
     
  • BTC-GBP

    19,414.47
    +622.34 (+3.31%)
     
  • CMC Crypto 200

    545.23
    -0.08 (-0.02%)
     
  • S&P 500

    4,178.56
    +59.35 (+1.44%)
     
  • DOW

    34,044.49
    -48.47 (-0.14%)
     
  • CRUDE OIL

    76.00
    -0.41 (-0.54%)
     
  • GOLD FUTURES

    1,940.40
    -2.40 (-0.12%)
     
  • NIKKEI 225

    27,402.05
    +55.17 (+0.20%)
     
  • HANG SENG

    21,958.36
    -113.82 (-0.52%)
     
  • DAX

    15,488.73
    +307.99 (+2.03%)
     
  • CAC 40

    7,166.22
    +89.11 (+1.26%)
     

Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $3 Billion by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1. 6 Billion in the year 2020, is projected to reach a revised size of US$3 Billion by 2027, growing at a CAGR of 9.

New York, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Myelodysplastic Syndrome (MDS) Drugs Industry" - https://www.reportlinker.com/p06032289/?utm_source=GNW
3% over the analysis period 2020-2027. Immunomodulatory Drugs, one of the segments analyzed in the report, is projected to record a 9.8% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hypomethylating Agents segment is readjusted to a revised 5.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $439.5 Million, While China is Forecast to Grow at 14.4% CAGR

The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$439.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$693.5 Million by the year 2027 trailing a CAGR of 14.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 8.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$418.2 Million by the year 2027.



Other Therapeutic Classes Segment to Record 14.2% CAGR

In the global Other Therapeutic Classes segment, USA, Canada, Japan, China and Europe will drive the 14.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$133.6 Million in the year 2020 will reach a projected size of US$319.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 16.3% CAGR through the analysis period.

Select Competitors (Total 34 Featured) -
Amgen
BluePoint Laboratories
Celgene Corporation
Celgene Europe Limited
Johnson & Johnson
Lupin Ltd Corporation
Otsuka America Pharmaceutical Inc.
Reddy’s Laboratories, Inc.
Sandoz
Shilpa Medicare Limited
Sun Pharmaceutical Industries Inc.
Takeda


Read the full report: https://www.reportlinker.com/p06032289/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Myelodysplastic Syndrome (MDS) Drugs - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Myelodysplastic Syndrome
(MDS) Drugs by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Immunomodulatory Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Immunomodulatory Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Immunomodulatory Drugs
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Hypomethylating Agents by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Hypomethylating Agents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Hypomethylating Agents
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Other Therapeutic Classes by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Other Therapeutic Classes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Other Therapeutic
Classes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 13: World Myelodysplastic Syndrome (MDS) Drugs Market
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2027

III. MARKET ANALYSIS

UNITED STATES
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2022 (E)
Table 14: USA Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 15: USA Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 16: USA 15-Year Perspective for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Percentage Breakdown of
Value Sales for Immunomodulatory Drugs, Hypomethylating Agents
and Other Therapeutic Classes for the Years 2012, 2021 & 2027

CANADA
Table 17: Canada Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 18: Canada Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 19: Canada 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

JAPAN
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 20: Japan Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 21: Japan Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 22: Japan 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

CHINA
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Table 23: China Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 24: China Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 25: China 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

EUROPE
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 26: Europe Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 27: Europe Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 28: Europe 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 29: Europe Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 30: Europe Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 31: Europe 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

FRANCE
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2022 (E)
Table 32: France Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 33: France Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 34: France 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

GERMANY
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 35: Germany Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Germany Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 37: Germany 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

ITALY
Table 38: Italy Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 39: Italy Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 40: Italy 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

UNITED KINGDOM
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2022 (E)
Table 41: UK Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 42: UK Historic Review for Myelodysplastic Syndrome (MDS)
Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 43: UK 15-Year Perspective for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Percentage Breakdown of
Value Sales for Immunomodulatory Drugs, Hypomethylating Agents
and Other Therapeutic Classes for the Years 2012, 2021 & 2027

SPAIN
Table 44: Spain Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 45: Spain Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 46: Spain 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

RUSSIA
Table 47: Russia Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 48: Russia Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 49: Russia 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

REST OF EUROPE
Table 50: Rest of Europe Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 51: Rest of Europe Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 52: Rest of Europe 15-Year Perspective for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Percentage Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

ASIA-PACIFIC
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2022 (E)
Table 53: Asia-Pacific Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 54: Asia-Pacific Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 55: Asia-Pacific 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 56: Asia-Pacific Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 57: Asia-Pacific Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 58: Asia-Pacific 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

AUSTRALIA
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Australia for 2022
(E)
Table 59: Australia Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 60: Australia Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 61: Australia 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

INDIA
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in India for 2022 (E)
Table 62: India Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 63: India Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 64: India 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

SOUTH KOREA
Table 65: South Korea Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 66: South Korea Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 67: South Korea 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

REST OF ASIA-PACIFIC
Table 68: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Myelodysplastic Syndrome (MDS) Drugs by
Therapeutic Class - Immunomodulatory Drugs, Hypomethylating
Agents and Other Therapeutic Classes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 69: Rest of Asia-Pacific Historic Review for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 70: Rest of Asia-Pacific 15-Year Perspective for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Percentage Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

LATIN AMERICA
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Latin America for
2022 (E)
Table 71: Latin America Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region -
Argentina, Brazil, Mexico and Rest of Latin America Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 72: Latin America Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 73: Latin America 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Percentage
Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest
of Latin America Markets for Years 2012, 2021 & 2027

Table 74: Latin America Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 75: Latin America Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 76: Latin America 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

ARGENTINA
Table 77: Argentina Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 78: Argentina Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 79: Argentina 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

BRAZIL
Table 80: Brazil Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 81: Brazil Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 82: Brazil 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

MEXICO
Table 83: Mexico Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 84: Mexico Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 85: Mexico 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

REST OF LATIN AMERICA
Table 86: Rest of Latin America Recent Past, Current & Future
Analysis for Myelodysplastic Syndrome (MDS) Drugs by
Therapeutic Class - Immunomodulatory Drugs, Hypomethylating
Agents and Other Therapeutic Classes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 87: Rest of Latin America Historic Review for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 88: Rest of Latin America 15-Year Perspective for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Percentage Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

MIDDLE EAST
Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Middle East for 2022
(E)
Table 89: Middle East Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region -
Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 90: Middle East Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 91: Middle East 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Geographic Region - Percentage
Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE
and Rest of Middle East Markets for Years 2012, 2021 & 2027

Table 92: Middle East Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 93: Middle East Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 94: Middle East 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

IRAN
Table 95: Iran Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 96: Iran Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 97: Iran 15-Year Perspective for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Percentage Breakdown of
Value Sales for Immunomodulatory Drugs, Hypomethylating Agents
and Other Therapeutic Classes for the Years 2012, 2021 & 2027

ISRAEL
Table 98: Israel Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 99: Israel Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 100: Israel 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

SAUDI ARABIA
Table 101: Saudi Arabia Recent Past, Current & Future Analysis
for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 102: Saudi Arabia Historic Review for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory
Drugs, Hypomethylating Agents and Other Therapeutic Classes
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 103: Saudi Arabia 15-Year Perspective for Myelodysplastic
Syndrome (MDS) Drugs by Therapeutic Class - Percentage
Breakdown of Value Sales for Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes for the
Years 2012, 2021 & 2027

UNITED ARAB EMIRATES
Table 104: UAE Recent Past, Current & Future Analysis for
Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class -
Immunomodulatory Drugs, Hypomethylating Agents and Other
Therapeutic Classes - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 105: UAE Historic Review for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs,
Hypomethylating Agents and Other Therapeutic Classes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 106: UAE 15-Year Perspective for Myelodysplastic Syndrome
(MDS) Drugs by Therapeutic Class - Percentage Breakdown of
Value Sales for Immunomodulatory Drugs, Hypomethylating Agents
and Other Therapeutic Classes for the Years 2012, 2021 & 2027

REST OF MIDDLE EAST
Table 107: Rest of Middle East Recent Past, Current & Future
Analysis for Myelodysplastic Syndrome (MDS) Drugs by
Therapeutic Class - Immunomodulatory Drugs, Hypomethylating
Agents and Other Therapeutic Classes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 108: Rest of Middle East Historic Review for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032289/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001